순환종양세포 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 검체별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)
Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application, By Specimen, By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1908208
리서치사
:
Grand View Research
발행일
:
2025년 12월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
순환종양세포 시장 개요
세계의 순환종양세포(CTC) 시장 규모는 2025년에 140억 4,000만 달러로 추정되며, 2033년에 389억 5,000만 달러에 달할 것으로 예측됩니다.
이는 순환종양세포(CTC)가 제공하는 비침습성과 이점으로 인해 2026-2033년 동안 CAGR 13.92%로 확대될 것으로 예상되기 때문입니다. 또한, 칩 기술의 기술적 진보도 시장 성장을 견인하는 중요한 요소입니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 순환종양세포 시장 변수, 동향과 범위
시장 계통 전망
시장 역학
순환종양세포 시장 분석 툴
산업 분석 : Porter's Five Forces
PESTEL 분석
제4장 순환종양세포 시장 : 기술별, 추정·동향 분석
세계의 순환종양세포 시장의 기술별 변동 분석
세계의 순환종양세포 시장 규모와 동향 분석(기술별, 2021-2033년)
이하 항목에 관한 시장 규모 및 예측과 동향 분석(2021-2033년)
CTC 검출·농축법
CTC 직접 검출법
CTC 분석
제5장 순환종양세포 시장 : 용도별, 추정·동향 분석
세계의 순환종양세포 시장의 용도별 변동 분석
세계의 순환종양세포 시장 규모와 동향 분석(용도별, 2021-2033년)
이하 항목에 관한 시장 규모 및 예측과 동향 분석(2021-2033년)
제6장 순환종양세포 시장 : 제품별, 추정·동향 분석
세계의 순환종양세포 시장의 제품별 변동 분석
세계의 순환종양세포 시장 규모와 동향 분석(제품별, 2021-2033년)
이하 항목에 관한 시장 규모 및 예측과 동향 분석(2021-2033년)
제7장 순환종양세포 시장 : 검체별, 추정·동향 분석
세계의 순환종양세포 시장의 검체별 변동 분석
세계의 순환종양세포 시장 규모와 동향 분석(검체별, 2021-2033년)
이하 항목에 관한 시장 규모 및 예측과 동향 분석(2021-2033년)
제8장 순환종양세포 시장 : 최종 용도별, 추정·동향 분석
세계의 순환종양세포 시장의 최종 용도별 변동 분석
세계의 순환종양세포 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
이하 항목에 관한 시장 규모 및 예측과 동향 분석(2021-2033년)
제9장 순환종양세포 시장 : 지역별, 추정·동향 분석
지역별 시장 점유율 분석(2025년과 2033년)
지역별 시장 대시보드
북미
유럽
영국
독일
프랑스
이탈리아
스페인
노르웨이
스웨덴
덴마크
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제10장 경쟁 구도
주요 시장 진입 기업의 최근 동향과 영향 분석
기업/경쟁 분류
주요 기업 포지션 분석(2025년 시점)
주요 기업 개요
QIAGEN
Bio-Techne Corp.
Precision Medicine Group, LLC.
Bio-Rad Laboratories, Inc.
Natera, Inc.
Illumina, Inc.
Cell Microsystems
Greiner Bio One International GmbH
Ikonisys Inc.
Miltenyi BIoTec
KSM
영문 목차
Circulating Tumor Cells Market Summary
The global circulating tumor cells market size was estimated at USD 14.04 billion in 2025 and is projected to reach USD 38.95 billion by 2033, expanding at a CAGR of 13.92% from 2026 to 2033, owing to the non-invasiveness and advantages offered by circulating tumor cells (CTC), it is considered a promising tool in cancer diagnosis. In addition, technological advancements in chip technology are another key factor driving market growth.
Global Circulating Tumor Cells Market Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global circulating tumor cells market on the basis of technology, application, product, specimen, end use, and region.
Technology Outlook (Revenue, USD Million, 2021 - 2033)
Circulating Tumor Cells CTC Detection & Enrichment Methods
Immunocapture (Label-based)
Positive Selection
Negative Selection
Size-based Separation (Label-free)Density-based Separation (Label-free)
Membrane-based
Microfluidic-based
Density-based Separation (Label-free)
Combined Methods
CTC Direct Detection Methods
CTC Analysis
Application Outlook (Revenue, USD Million, 2021 - 2033)
Clinical
Risk Assessment
Screening and Monitoring
Research
Cancer Stem Cell & Tumorogenesis Research
Drug/Therapy Development
Product Outlook (Revenue, USD Million, 2021 - 2033)
Kits & Reagents
Blood Collection Tubes
Devices or Systems
Specimen Outlook (Revenue, USD Million, 2021 - 2033)
Blood
Bone Marrow
Other Body Fluids
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Research and Academic Institutes
Hospital and Clinics
Diagnostic Centers
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Middle East and Africa (MEA)
South Africa
UAE
Saudi Arabia
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Product
1.2.4. Specimen
1.2.5. End use
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in chip technology
3.2.1.2. Expanding applications of CTCs
3.2.1.3. Growing demand for early and rapid cancer diagnosis
3.2.1.4. Growing incidence of cancer
3.2.2. Market restraint analysis
3.2.2.1. Consistency-related challenges in CTC detection and enrichment
3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
3.2.2.3. Lower applicability of CTCs in rare cancers
3.3. Circulating Tumor Cells Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis
4.1. Technology Segment Dashboard
4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. CTC Detection & Enrichment Methods
4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2. Immunocapture (Label-based)
4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2.2. Positive Selection
4.4.1.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2.3. Negative Selection
4.4.1.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.3. Size-based Separation (Label-free)
4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.3.2. Membrane-based
4.4.1.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.3.3. Microfluidic-based
4.4.1.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.4. Density-based Separation (Label-free)
4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.5. Combined Methods
4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. CTC Direct Detection Methods
4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.2. SERS
4.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.3. Microscopy
4.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. CTC Analysis
4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. Global Circulating Tumor Cells Market Application Movement Analysis
5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Clinical
5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.2. Risk Assessment
5.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.3. Screening and Monitoring
5.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Research
5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
5.4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.3. Drug/Therapy Development
5.4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis
6.1. Product Segment Dashboard
6.2. Global Circulating Tumor Cells Market Product Movement Analysis
6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Kits & reagents
6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Blood collection tubes
6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Devices or systems
6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis
7.1. Specimen Segment Dashboard
7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2021 to 2033 (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.4.1. Blood
7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. Bone marrow
7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. Other body fluids
7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis
8.1. End Use Segment Dashboard
8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
8.4.1. Research and academic institutes
8.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. Hospital and clinics
8.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Diagnostic centers
8.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2025 & 2033
9.2. Regional Market Dashboard
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
9.3.1.5. Target disease prevalence
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
9.3.3.5. Target disease prevalence
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
9.4.1.5. Target disease prevalence
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
9.4.7.5. Target disease prevalence
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
9.4.8.5. Target disease prevalence
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
9.5.1.5. Target disease prevalence
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
9.5.4.5. Target disease prevalence
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
9.5.5.5. Target disease prevalence
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
9.5.6.5. Target disease prevalence
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
9.6.1.5. Target disease prevalence
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
9.6.2.5. Target disease prevalence
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
9.7.1.5. Target disease prevalence
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
9.7.2.5. Target disease prevalence
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
9.7.3.5. Target disease prevalence
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
9.7.4.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Key company position analysis, 2025
10.4. Key Company Profiles
10.4.1. QIAGEN
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Bio-Techne Corp.
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Precision Medicine Group, LLC.
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Bio-Rad Laboratories, Inc.
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Natera, Inc.
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Illumina, Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Cell Microsystems
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Greiner Bio One International GmbH
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Ikonisys Inc.
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Miltenyi Biotec
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
관련자료
